Q-omics provides the consensus-scored RPL41P2 profile across patient tissues and cancer cell-line models. RPL41P2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPL41P2 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, RPL41P2 RNA expression shows 16,042 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where RPL41P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL41P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL41P2 survival associations across molecular data types. RPL41P2 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL41P2 RNA expression–survival associations across cancer types. High RPL41P2 expression shows unfavorable associations in ACC, KIRP and LIHC, but favorable associations in LUSC, THCA and CESC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPL41P2 RNA expression.
This table summarizes RPL41P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL41P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL41P2 shows lower tumor expression in BRCA and higher tumor expression in KIRC, COAD, LIHC, CHOL and LUAD. The KIRC box plot shows higher RPL41P2 RNA expression in tumor versus normal tissue (log2 FC = +0.677, t-test p < 0.001).
This table shows molecular features associated with RPL41P2 in patient tissues and cancer cell lines. In patient samples, RPL41P2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
